{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:58:46Z","timestamp":1757624326207,"version":"3.44.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims:<\/jats:title>\n            <jats:p>Cardiac tumors are aggressive and asymptomatic in early stages, causing late diagnosis and locoregional metastasis. Currently, the standard of care uses gadolinium-based contrast agents for MRI, and the associated hypersensitivity reactions are a significant concern, such as gadolinium deposition disease. In addition, the proximity of cardiac lesions closer to vital structures complicates surgical interventions. We envisage the development of a scalable, Gd-free, multimodal contrast agent based on EDTA bisamide with pyridine-based fluorophore (L1). The diagnostic arm should have manganese (Mn)-enhanced high relaxivity for MRI and high sensitivity for PET and\/or optical imaging (eg, fluorescence lifetime imaging), with comparable\/higher than commercial diagnostic agents, along with the multikinase targeted anticancer activity and strong affinity for human serum albumin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and Methods:<\/jats:title>\n            <jats:p>Mn complex of EDTA bisamide of 4-(aminomethyl)pyridine (L1), MnL1, was reproduced in high yield (77%) and purity (98%), characterized by liquid chromatography-mass spectrometry (LC-MS). The solubility in water and stability in sodium acetate buffer were evaluated. T1 mapping followed by static and dynamic contrast-enhanced MRI (DCE_MRI) image acquisition, post-tail vein injection of healthy C57BL\/6 mice through I.V. with 1mM of MnL1\/PBS was carried out by 3T-MRI (BioSpec, Bruker), wherein standard gadobutrol was used as control. Optical properties of L1 dissolved in solvent mixtures of dimethyl sulfoxide were optimized using PhotonIMAGER RT OPTIMA by Biospace Lab with AlexaFluor750 as the positive control. Docking studies with FAP and EGFR kinases were conducted by AutoDock Vina, followed by MD simulation (My Presto).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>LC-MS: The highest UV absorption peak was correlated to more than 80% relative abundance of the highest molecular ion peak in mass spectra (cal: 525.18234; found 525.750), indicating strong chelation of L1 to Mn (II). 3T-MRI data of MnL1 revealed comparable performance with a standard gadobutrol. L1 exhibited multiple excitation wavelengths and NIR1 emission. DCE-MRI revealed contrasting dynamics with strong uptake in the kidney, liver, and heart. Docking studies revealed inhibition of FAP (allosteric) and EGFR (\u22127.0 and 6.7 Kcal\/mol), validated by their respective cocrystallized ligands and commercial standards and by MD simulation, reflecting constant gyration ratios and strong hydrogen bonding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Preclinical MRI imaging justified the efficacy of Mn(II)L1. L1 validated as a promising visible and NIR1dye along with its ability to bind and inhibit pan-cancer targets, FAP (allosteric) and EGFR kinases. Previously validated features of lifetime sensing\/high stokes shift and Cu (II) quenching are also noteworthy. Dual-echo acquisitions for quantitative DCE-MRI as a standalone (with T2* corrections) or in combination with PET\/MRI of <jats:sup>64<\/jats:sup>Cu-L1(separately studied) or as <jats:sup>52<\/jats:sup>MnL1 by single injection envisaged. T1 mapping for therapy response monitoring based on the reduction of native tumor T1 upon binding of MnL1 to the kinase is hereby envisaged for the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rmr.0000000000000321","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:00:07Z","timestamp":1757419207000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Investigations Toward Gd-free Molecularly Targeted Dual-Modal, MRI Dynamic (DCE-MRI)\/Optical Imaging Contrast Agent for Cardiac Angiosarcoma"],"prefix":"10.1097","volume":"34","author":[{"given":"CuhaWijay","family":"Sathiyajith","sequence":"first","affiliation":[{"name":"SAAINNOVATE, Sydney, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Jensen","sequence":"additional","affiliation":[{"name":"Hevesy Laboratory, DTU Health Technology, Technical University of Denmark, Ris\u00f8, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"B\u00e9n\u00e9chet","sequence":"additional","affiliation":[{"name":"Department of Training and Research, Faculty of Biology and Medicine, In Vivo Imaging Facility (IVIF), University Hospital, Lausanne (UNIL), Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilia Di","family":"Domenicantonio","sequence":"additional","affiliation":[{"name":"Department of Training and Research, Faculty of Biology and Medicine, In Vivo Imaging Facility (IVIF), University Hospital, Lausanne (UNIL), Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anikitos","family":"Garofalakis","sequence":"additional","affiliation":[{"name":"BIOSPACE LAB, Nesles-la-Vall\u00e9e, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Tchicaya","sequence":"additional","affiliation":[{"name":"BIOSPACE LAB, Nesles-la-Vall\u00e9e, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10]]},"reference":[{"issue":"2","key":"R1-20250909","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/ijms25021201","article-title":"An overview of advances in rare cancer diagnosis and treatment","volume":"25","author":"Christyani","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"R2-20250909","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/biomedicines9070774","article-title":"Primary soft tissue sarcoma of the heart: an emerging chapter in cardio-oncology","volume":"9","author":"Scicchitano","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"R3-20250909","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/ncpcardio0653","article-title":"Therapy insight: malignant primary cardiac tumors","volume":"3","author":"Reardon","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"3","key":"R4-20250909","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/hearts5030028","article-title":"Clinical pathophysiology and research highlights of cardiac angiosarcoma: obligation for immunogenetic profiling to understand their growth pattern and tailor therapies","volume":"5","author":"Kanuri","year":"2024","journal-title":"Hearts"},{"issue":"4","key":"R5-20250909","first-page":"1504","article-title":"Multimodality imaging to distinguish between benign and malignant cardiac masses","volume":"29","author":"Aghayev","year":"2022","journal-title":"J Nucl Cardiol official Publ Am Soc Nucl Cardiol"},{"issue":"7","key":"R6-20250909","first-page":"e41947","article-title":"Primary cardiac angiosarcoma: a Review","volume":"15","author":"Kumari","year":"2023","journal-title":"Cureus"},{"key":"R7-20250909","doi-asserted-by":"crossref","first-page":"591512","DOI":"10.1155\/2009\/591512","article-title":"Primary cardiac angiosarcoma: a fatal disease","volume":"2009","author":"Antonuzzo","year":"2009","journal-title":"Case Rep Med"},{"issue":"2","key":"R8-20250909","doi-asserted-by":"crossref","first-page":"86","DOI":"10.15420\/cfr.2017:19:1","article-title":"The prognostic role of tissue characterisation using cardiovascular magnetic resonance in heart failure","volume":"3","author":"Adam","year":"2017","journal-title":"Card Fail Rev"},{"issue":"1","key":"R9-20250909","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ahj.2005.08.021","article-title":"Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation","volume":"152","author":"Srichai","year":"2006","journal-title":"Am Heart J"},{"issue":"6","key":"R10-20250909","first-page":"856","article-title":"Differentiation of malignant and benign cardiac tumors using 18F-FDG PET\/CT","volume":"53","author":"Rahbar","year":"2012","journal-title":"J Nucl Med official Publ Soc Nucl Med"},{"issue":"5","key":"R11-20250909","doi-asserted-by":"crossref","first-page":"e003368","DOI":"10.1161\/JAHA.116.003368","article-title":"Pattern and prognostic implications of cardiac metastases among patients with advanced systemic cancer assessed with cardiac magnetic resonance imaging","volume":"5","author":"Pun","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"R12-20250909","doi-asserted-by":"crossref","first-page":"e011709","DOI":"10.1161\/JAHA.118.011709","article-title":"Late gadolinium enhancement cardiac magnetic resonance tissue characterization for cancer\u2010associated cardiac masses: metabolic and prognostic manifestations in relation to whole\u2010body positron emission tomography","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"12","key":"R13-20250909","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/eurheartj\/ehr104","article-title":"Cardiovascular magnetic resonance imaging for diagnosis and clinical management of suspected cardiac masses and tumours","volume":"32","author":"Fussen","year":"2011","journal-title":"Eur Heart J"},{"issue":"2","key":"R14-20250909","first-page":"147","article-title":"Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion","volume":"4","author":"Gordon","year":"2014","journal-title":"Cardiovasc Diagn Ther"},{"issue":"5","key":"R15-20250909","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.mri.2014.02.003","article-title":"The precision of DCE-MRI using the tissue homogeneity model with continuous formulation of the perfusion parameters","volume":"32","author":"Barto\u0161","year":"2014","journal-title":"Magn Reson Imaging"},{"issue":"6","key":"R16-20250909","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.rli.0000209607.99200.53","article-title":"Determination of pharmacokinetic parameters in DCE MRI: consequence of nonlinearity between contrast agent concentration and signal intensity","volume":"41","author":"Heilmann","year":"2006","journal-title":"Invest Radiol"},{"issue":"1","key":"R17-20250909","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1038\/s41598-023-36483-9","article-title":"Dynamic contrast enhanced (DCE) MRI estimation of vascular parameters using knowledge-based adaptive models","volume":"13","author":"Bagher-Ebadian","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"R18-20250909","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.7150\/thno.43227","article-title":"Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study","volume":"10","author":"Voskuil","year":"2020","journal-title":"Theranostics"},{"issue":"4","key":"R19-20250909","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/15533506221074601","article-title":"Fluorescence imaging using methylene blue sentinel lymph node biopsy in melanoma","volume":"29","author":"Cwalinski","year":"2022","journal-title":"Surg Innov"},{"issue":"5","key":"R20-20250909","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1227\/NEU.0000000000000929","article-title":"What is the surgical benefit of utilizing 5-ALA for fluorescence-guided surgery of malignant gliomas?","volume":"77","author":"Hadjipanayis","year":"2015","journal-title":"Neurosurgery"},{"issue":"1","key":"R21-20250909","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41698-024-00699-3","article-title":"Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence","volume":"8","author":"Cheng","year":"2024","journal-title":"Npj Precis Oncol"},{"key":"R22-20250909","first-page":"119430C","article-title":"Dynamic contrast-enhanced fluorescence imaging compared with MR imaging in evaluating bone perfusion during open orthopedic surgery","volume":"11943","author":"Tang","year":"2022","journal-title":"Proc Spie Int Soc Opt Eng"},{"issue":"2","key":"R23-20250909","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.2349\/biij.2.2.e8","article-title":"Molecular magnetic resonance imaging","volume":"2","author":"Hengerer","year":"2006","journal-title":"Biomed Imaging Interv J"},{"issue":"2","key":"R24-20250909","first-page":"33","article-title":"Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives","volume":"6","author":"Khan","year":"2018","journal-title":"Med Sci"},{"issue":"43","key":"R25-20250909","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.1002\/anie.200700700","article-title":"Collagen-targeted MRI contrast agent for molecular imaging of fibrosis","volume":"46","author":"Caravan","year":"2007","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"R26-20250909","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/chem.201801578","article-title":"Molecular probes for imaging fibrosis and fibrogenesis","volume":"25","author":"D\u00e9sog\u00e8re","year":"2019","journal-title":"Chemistry"},{"issue":"13","key":"R27-20250909","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.826388","article-title":"Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model","volume":"119","author":"Spuentrup","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"R28-20250909","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/RLI.0000000000000731","article-title":"Molecular MR contrast agents","volume":"56","author":"Shuvaev","year":"2021","journal-title":"Invest Radiol"},{"issue":"1","key":"R29-20250909","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Med"},{"key":"R30-20250909","doi-asserted-by":"crossref","first-page":"100307","DOI":"10.1016\/j.rechem.2022.100307","article-title":"Synthesis, photophysical characterization, relaxometric studies and molecular docking studies of gadolinium-free contrast agents for dual modal imaging","volume":"4","author":"Sathiyajith","year":"2022","journal-title":"Results Chem"},{"key":"R31-20250909","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejmp.2020.11.023","article-title":"Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent","volume":"81","author":"Zhou","year":"2021","journal-title":"Physica Med"},{"issue":"4","key":"R32-20250909","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/nbm.1784","article-title":"Quantitative dynamic contrast-enhanced MRI for mouse models using automatic detection of the arterial input function","volume":"25","author":"Kim","year":"2012","journal-title":"NMR Biomed"},{"issue":"12","key":"R33-20250909","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1002\/cam4.2369","article-title":"Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis","volume":"8","author":"Okuchi","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"R34-20250909","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1470-2045(06)71012-9","article-title":"Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy","volume":"8","author":"Zahra","year":"2007","journal-title":"Lancet Oncol"},{"issue":"11","key":"R35-20250909","doi-asserted-by":"crossref","first-page":"e2003987","DOI":"10.1002\/advs.202003987","article-title":"Myocardial viability imaging using manganese-enhanced mri in the first hours after myocardial infarction","volume":"8","author":"Jasmin","year":"2021","journal-title":"Adv Sci"},{"issue":"4","key":"R37-20250909","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2214\/AJR.11.7118","article-title":"Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI","volume":"198","author":"De Cobelli","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R38-20250909","doi-asserted-by":"crossref","first-page":"917180","DOI":"10.3389\/fcvm.2022.917180","article-title":"Cardiac phase-resolved late gadolinium enhancement imaging","volume":"9","author":"Weing\u00e4rtner","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"R40-20250909","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40261-018-0674-9","article-title":"Gadobutrol: a review in contrast-enhanced MRI and MRA","volume":"38","author":"Scott","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"1","key":"R41-20250909","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3174\/ajnr.A4154","article-title":"Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)","volume":"36","author":"Maravilla","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"R42-20250909","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/pharmaceutics4030442","article-title":"Practical dynamic contrast enhanced mri in small animal models of cancer: data acquisition, data analysis, and interpretation","volume":"4","author":"Barnes","year":"2012","journal-title":"Pharmaceutics"},{"issue":"2","key":"R43-20250909","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/RMR.0b013e3180f617af","article-title":"Cardiac magnetic resonance imaging at 3.0 T","volume":"18","author":"Fenchel","year":"2007","journal-title":"Top Magn Reson Imaging"},{"issue":"6","key":"R44-20250909","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3348\/kjr.2018.19.6.1007","article-title":"Comparison of the diagnostic accuracies of 1.5T and 3T stress myocardial perfusion cardiovascular magnetic resonance for detecting significant coronary artery disease","volume":"19","author":"Min","year":"2018","journal-title":"Korean J Radiol"},{"key":"R46-20250909","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2025.05.058","article-title":"Beyond Gadolinium: The Potential of Manganese Nanosystems in MRI and Multimodal Imaging Agents","author":"Tei","year":"2025","journal-title":"Acta Biomater"},{"key":"R47-20250909","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.actbio.2018.05.017","article-title":"Near-infrared light-activated red-emitting upconverting nanoplatform for T1-weighted magnetic resonance imaging and photodynamic therapy","volume":"74","author":"Tang","year":"2018","journal-title":"Acta Biomater"},{"issue":"3","key":"R48-20250909","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.biomaterials.2011.10.005","article-title":"Targeted non-covalent self-assembled nanoparticles based on human serum albumin","volume":"33","author":"Bunschoten","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"R49-20250909","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The Role of VEGF and EGFR inhibition: implications for combining anti\u2013VEGF and Anti\u2013EGFR Agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"13","key":"R50-20250909","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/eurheartj\/ehaa931","article-title":"Cardiac angiosarcoma detected using 68 Ga-fibroblast activation protein inhibitor positron emission tomography\/magnetic resonance","volume":"42","author":"Zhao","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"R51-20250909","doi-asserted-by":"crossref","first-page":"e0174351","DOI":"10.1371\/journal.pone.0174351","article-title":"Biodistribution and PET imaging of pharmacokinetics of manganese in mice using Manganese-52","volume":"12","author":"Wooten","year":"2017","journal-title":"PLoS One"},{"issue":"40","key":"R52-20250909","doi-asserted-by":"crossref","first-page":"eadf0837","DOI":"10.1126\/sciadv.adf0837","article-title":"Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets","volume":"9","author":"Su","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"R53-20250909","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1038\/s41598-022-07000-1","article-title":"Bridging the macro to micro resolution gap with angiographic optical coherence tomography and dynamic contrast enhanced MRI","volume":"12","author":"Zabel","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"R54-20250909","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/bios13100939","article-title":"Quantitative imaging of genetically encoded fluorescence lifetime biosensors","volume":"13","author":"Vu","year":"2023","journal-title":"Biosensors"}],"container-title":["Topics in Magnetic Resonance Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RMR.0000000000000321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:00:13Z","timestamp":1757419213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RMR.0000000000000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rmr.0000000000000321","relation":{},"ISSN":["1536-1004"],"issn-type":[{"value":"1536-1004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"2025-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}